Implications of expanding indications for drug treatment to prevent fracture in older men in United States: Cross sectional and longitudinal analysis of prospective cohort study

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Ensrud, Kristine E ^a,b   Taylor, Brent C ^a,b   Peters, Katherine W ^c   Gourlay, Margaret L ^d   Donaldson, Meghan G ^e   Leslie, William D ^f   Blackwell, Terri L ^c   Fink, Howard A ^a,b   Orwoll, Eric S ^g   Schousboe, John ^h,i  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h PARK NICOLLET CLINIC   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AGED; ALGORITHM; ARTICLE; BONE DENSITY; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMPUTER PREDICTION; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG INDICATION; FEMUR NECK FRACTURE; FRAGILITY FRACTURE; GERIATRIC CARE; GERIATRIC PATIENT; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; INCIDENCE; INTERMETHOD COMPARISON; INTERVENTION STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OSTEOPOROSIS; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SPINE FRACTURE; UNITED STATES; VERY ELDERLY; WORLD HEALTH ORGANIZATION CRITERIA; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY; CHEMOPREVENTION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; OSTEOPOROTIC FRACTURES; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84903643294     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4120     Document Type: Article

References (60)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75. (Pubitemid 46797130)
2. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(suppl 2):S3-7. (Pubitemid 46232115)
3. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18:1947-54. (Pubitemid 37377443)
4. Ebeling PR. Osteoporosis in men. N Engl J Med 2008;358:1474-82.
5. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 1994;843:1-129.
6. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ III, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008;42:467-75.
7. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. NOF, 2010 (available at www.nof.org/files/nof/public/ content/file/344/upload/159.pdf).
8. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. NOF, 2014 (available at http://nof.org/files/nof/ public/content/file/2791/upload/919.pdf).
9. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802-22.
10. International Society for Clinical Densitometry. 2013 ISCD official positions - adult. www.iscd.org/official-positions/2013-iscd-official-positions- adult/.
11. Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 2011;22:2789-98.
12. Richy F, Gourlay ML, Garrett J, Hanson L, Reginster JY. Osteoporosis prevalence in men varies by the normative reference. J Clin Densitom 2004;7:127-33. (Pubitemid 38850389)
13. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009;24:719-25.
14. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-23.
15. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10. (Pubitemid 30659471)
16. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012;97:3161-9.
17. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17. (Pubitemid 36008334)
18. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213. (Pubitemid 351665507)
19. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809. (Pubitemid 350044800)
20. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36. (Pubitemid 34615775)
21. FRAX WHO Fracture Risk Assessment Tool. 2011. www.shef.ac.uk/FRAX/.
22. Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, 2007 (available at www.shef.ac.uk/FRAX/pdfs/WHO-Technical-Report.pdf).
23. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone 2009;44:734-43.
24. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, et al. Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R): executive summary of the 2010 Position Development Conference on Interpretation and use of FRAX(R) in clinical practice. J Clin Densitom 2011;14:171-80.
25. Endocrine Society. The Endocrine Society's statement on industry relationships. 2009. www.endocrine.org/aaaa/media/endosociety/Files/About%20Us/ Corporate%20Info/The-Endocrine-Society-s-Statement-on-Industry-Relationships- Final-11-13-09.pdf.
26. International Osteoporosis Foundation. Annual report 2012. IOF, 2013 (available at www.iofbonehealth.org/sites/default/files/PDFs/2012-IOF-Annual- Report%5BWEB%5D-0.pdf).
27. National Osteoporosis Foundation. 2012 annual report. NOF, 2013 (available at http://nof.org/files/nof/public/content/report/1820/file/851.pdf).
28. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97.
29. Tosteson AN, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19:437-47.
30. Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 2005;26:557-68. (Pubitemid 41242401)
31. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study - a large observational study of the determinants of fracture in older men. Contemp Clin Trials 2005;26:569-85. (Pubitemid 41242402)
32. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994;10:405-11. (Pubitemid 24339205)
33. Cawthon PM, Ewing SK, McCulloch CE, Ensrud KE, Cauley JA, Cummings SR, et al. Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 2009;24:1728-35.
34. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-89. (Pubitemid 28486716)
35. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-8. (Pubitemid 27500187)
36. International Society for Clinical Densitometry. 2007 ISCD official positions - adult. www.iscd.org/official-positions/2007-iscd-official-positions- adult/.
37. Kelly TL. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990;5:S249.
38. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004;4:103-12.
39. Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 2002;5:87-93. (Pubitemid 34297902)
40. Looker AC, Melton LJ III, Borrud LG, Shepherd JA. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int 2012;23:1351-60.
41. Johnell O, Kanis JA, Oden A, Johansson H, De LC, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94. (Pubitemid 40863806)
42. Binkley NC, Schmeer P, Wasnich RD, Lenchik L. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom 2002;5(suppl):S19-27. (Pubitemid 35193051)
43. Berry SD, Kiel DP, Donaldson MG, Cummings SR, Kanis JA, Johansson H, et al. Application of the National Osteoporosis Foundation guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int 2010;21:53-60.
44. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, et al. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 2010;25:1506-11.
45. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.
46. McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007;22:135-41. (Pubitemid 46032606)
47. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82. (Pubitemid 29014065)
48. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al, for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40. (Pubitemid 32107641)
49. McClung MR, Boonen S, Torring O, Roux C, Rizzoli R, Bone HG, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012;27:211-8.
50. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010;47:729-35.
51. Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial. J Bone Miner Res 2012;27:1804-10.
52. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012;27:1480-6.
53. McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy - additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009;20:811-7.
54. Ettinger B, Ensrud KE, Blackwell T, Curtis JR, Lapidus JA, Orwoll ES. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 2013;24:1185-93.
55. Douglas F, Petrie KJ, Cundy T, Horne A, Gamble G, Grey A. Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors. Osteoporos Int 2012;23:2135-40.
56. Rubin KH, Friis-Holmberg T, Hermann AP, Abrahamsen B, Brixen K. Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. J Bone Miner Res 2013;28:1701-17.
57. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8.
58. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013;75:392-6.
59. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
60. Ensrud KE, Schousboe JT. Vertebral fractures. N Engl J Med 2011;364:1634-42.